Accelerating precision therapies through digital infrastructure for adaptive trials and trial-ready cohort studies
The project is a feasibility study for the development of a national digital infrastructure to support adaptive clinical trials and ‘trial-ready’ natural history cohort studies for a number of rare diseases.
The digital study is an open-source solution that will improve efficiencies and seamlessly capture patient-reported data in drug evaluation through trial enrolment and data collection. It will establish linkage of clinician-entered, health system administrative data into a patient record, supporting the efficient systematic capture of data for trials, and enabling real-time Bayesian analysis for novel trial designs. The project facilitated capture of clinical evidence to inform the licensure and funding of new therapeutic products for an initial three rare-diseases.
State | Queensland |
Consortium lead | Queensland University of Technology |
Consortium members | Murdoch University, Telethon Kids Institute, MNDi Foundation & Foundation for Angelman Syndrome Therapeutics Australia |
MTPConnect grant | $200,000 |
Industry contribution | $446,072 |
Project duration | June 2018 - November 2020 (Finished) |
Contact | Professor Matt Bellgard, Queensland University of Technology matthew.bellgard@qut.edu.au |
Visit Queensland University of Technology for more details.
Twitter: QUT | LinkedIn: QUT (Queensland University of Technology)